- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05564520
International Multicenter Study on Lipin-1 Deficiency (LIPIN1)
February 28, 2024 updated by: Imagine Institute
Etude Multicentrique Internationale Sur le déficit en Lipin-1
LIPIN1 is an international registry that allows the collection of data on the follow-up, management and treatment of patients with Lipin-1 deficiency.
Study Overview
Status
Recruiting
Conditions
Detailed Description
This study evaluates survival, cardiac function, quality of life, fatigability, treatment tolerance and comparison of the efficacy of different current treatments in patients with Lipin-1 deficiency.
Study Type
Observational
Enrollment (Estimated)
150
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hortense DE CALBIAC, Ph.D.
- Email: hortense.de-calbiac@institutimagine.org
Study Contact Backup
- Name: Pascale De Lonlay, Pr
- Phone Number: +33 (0)1 44 49 40 23
- Email: pascale.delonlay@aphp.fr
Study Locations
-
-
-
Paris, France, 75015
- Recruiting
- Necker - Enfants Malades Hospital
-
Contact:
- Pascale De Lonlay, Pr
-
Contact:
- Caroline Tuchmann-Durand, Pharm D
- Phone Number: + 33 (0)1 71 19 60 18
- Email: caroline.tuchmann-durand@institutimagine.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patient with lipin1 deficit with two mutations on the LIPIN1 gene and having undergone acute rhabdomyolysis, 50 to 150 patients
Description
Inclusion Criteria:
Patient at least 12 months with Lipin1 deficiency confirmed by molecular biology (two causal mutations in the LPIN1 gene)
Exclusion Criteria:
Opposition of the patient or his parents to participate to the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of survival in patients with Lipin-1 deficiency
Time Frame: According to routine care
|
Patient survival as assessed by long-term follow-up
|
According to routine care
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of cardiac function in patients with Lipin-1 deficiency
Time Frame: According to routine care
|
Cardiac function, assessed by cardiographic ultrasound
|
According to routine care
|
Comparison of the effectiveness of different current treatments in patients with Lipin-1 deficiency
Time Frame: According to routine care
|
Comparison of the number of severe rhabdomyolysis and biological assessment (CPK measurement performed as part of care) in patients
|
According to routine care
|
Evaluation of the quality of life of patients with Lipin-1 deficiency
Time Frame: According to routine care
|
Quality of life, assessed by standardized questionnaires
|
According to routine care
|
Evaluation of the tolerance of treatments in patients with Lipin-1 deficiency.
Time Frame: According to routine care
|
Treatment side effects, assessed by abdominal pain, skin allergy and other adverse effects
|
According to routine care
|
Evaluation the fatigability of patients with Lipin-1 deficiency
Time Frame: According to routine care
|
Exercise capacity, assessed by walking tests
|
According to routine care
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Pascale De Lonlay, Pr, Necker Hospital
- Study Chair: Hortense De Calbiac, Ph.D., Institut Imagine
- Study Chair: Caroline Tuchmann-Durand, Pharm D, Institut Imagine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 24, 2023
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
December 31, 2026
Study Registration Dates
First Submitted
September 27, 2022
First Submitted That Met QC Criteria
September 29, 2022
First Posted (Actual)
October 3, 2022
Study Record Updates
Last Update Posted (Estimated)
February 29, 2024
Last Update Submitted That Met QC Criteria
February 28, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- HJ-23-LIPIN1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lipin-1 Deficiency
-
IpsenRecruitingIGF1 DeficiencySpain, United States, Italy, France, United Kingdom, Germany, Austria, French Guiana, Poland, Sweden, Martinique
-
IpsenTerminatedIGF-1 DeficiencySpain
-
University of Texas Southwestern Medical CenterRecruitingGlucose Transporter Type 1 Deficiency Syndrome | GLUT1 Deficiency Syndrome | Glucose Transporter type1 (GLUT-1) Deficiency | GLUT-1 Deficiency SyndromeUnited States
-
University of Texas Southwestern Medical CenterRecruitingGlucose Metabolism Disorders | Epilepsy | Glucose Transporter Type 1 Deficiency Syndrome | Glut1 Deficiency Syndrome 1 | Glut1 Deficiency Syndrome 1, Autosomal Recessive | Glucose Transporter Protein Type 1 Deficiency Syndrome | Glucose Transport DefectUnited States
-
Hospices Civils de LyonCompleted
-
Juan PascualNational Institute of Neurological Disorders and Stroke (NINDS)CompletedGlucose Metabolism Disorders | Epilepsy | Glucose Transporter Type 1 Deficiency Syndrome | Glut1 Deficiency Syndrome 1, Autosomal Recessive | Glucose Transporter Protein Type 1 Deficiency Syndrome | Glucose Transport Defect | GLUT1DS1United States
-
Assiut UniversityUnknown
-
Thomayer University HospitalMasaryk UniversityRecruiting
-
University of Texas Southwestern Medical CenterNational Institute of Neurological Disorders and Stroke (NINDS)Active, not recruitingGlucose Metabolism Disorders | Epilepsy | Glucose Transporter Type 1 Deficiency Syndrome | Glut1 Deficiency Syndrome 1, Autosomal Recessive | Glucose Transporter Protein Type 1 Deficiency Syndrome | Glucose Transport Defect | GLUT1DS1United States
-
University of FloridaAlpha-1 FoundationEnrolling by invitation